AUSTIN, Texas, Oct. 25 /PRNewswire-FirstCall/ -- (Nasdaq: VRML) -- Fred Ueland, M.D., Associate Professor of Gynecologic Oncology at the University of Kentucky's Markey Cancer Center, and principal investigator of the multi-center OVA1™ clinical trial, today presented data demonstrating the high sensitivity of the OVA1 test at the 13th Annual International Gynecologic Cancer Society Meeting being held in Prague, October 23-26.
Dr. Ueland's presentation demonstrated that OVA1 had sensitivity for ovarian cancer of 92.5%, as compared to 68.9% for CA125 using cutoffs established in the ACOG criteria for adnexal mass evaluation and 77.0% for CA125 using cutoffs in the modified ACOG criteria. Additionally, OVA1 detected 23/24 stage I epithelial ovarian cancers (EOC) and 17/17 stage II epithelial ovarian cancer, for an overall sensitivity of 97.6% for early stage EOC, as compared to 65.9% for CA125 using the ACOG cutoffs. The improvement in sensitivity was even greater among premenopausal women; for OVA1, sensitivity for early stage EOC was 92.9% and for CA125, sensitivity was 35.7%. Overall, OVA1 detected 76% of malignancies missed by CA125, including all advanced stage malignancies.
"Studies show that women have more favorable outcomes when surgery for ovarian cancer is performed by a gynecologic oncologist," explained Dr. Ueland. "The current research further demonstrates that OVA1 will not only help identify more women with ovarian cancer for referral, but can give them greater confidence that their ovarian tumor is benign."
"Because of the high mortality from ovarian cancer, clinical sensitivity for malignancy is paramount," said Gail S. Page, Chair and Chief Executive Officer of Vermillion, Inc. "These data further support the clinical utility of OVA1 as an adjunctive tool to aid physicians in the assessment of women with an adnexal mass for whom surg
|SOURCE Vermillion, Inc.|
Copyright©2010 PR Newswire.
All rights reserved